0001209191-19-029182.txt : 20190513
0001209191-19-029182.hdr.sgml : 20190513
20190513091540
ACCESSION NUMBER: 0001209191-19-029182
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190510
FILED AS OF DATE: 20190513
DATE AS OF CHANGE: 20190513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clayman Michael D.
CENTRAL INDEX KEY: 0001597407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 19817050
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-10
0
0001419600
Flexion Therapeutics Inc
FLXN
0001597407
Clayman Michael D.
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
1
1
0
0
President and CEO
Common Stock
2019-05-10
4
P
0
4012
12.4794
A
74868
D
Common Stock
314066
I
By the Michael D.Clayman 2006 Revocable Trust
Common Stock
24600
I
By the Michael D. Clayman Irrevocable Trust
Common Stock
388683
I
By Versant Development Fund III, LLC
The weighted average purchase price for the transaction reported was $12.47940, and the range of prices were between $12.470 and $12.481. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
/s/Mark S. Levine, Attorney-in-Fact
2019-05-13